Revelation Biosciences, Inc. Common Stock
REVBStock
$1.13−90.55%52W
Market Cap$4.26M
P/E—
Div yield—
Beta-0.18
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-80.41%
Price vs S&P 500 (4W)5.33%
VGM Score30.07
Market Capitalization$4.26M
Earnings Surprise History
Q1 26-2.71est. -1.17
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
REVBRevelation Biosciences, Inc. Common Stock | — | — | D | $1.13 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Revelation Biosciences is a clinical-stage biotech company developing immunology-based treatments using Gemini, a proprietary TLR4 agonist designed to modulate inflammatory responses for therapeutic benefit. The company's pipeline includes three Gemini-based programs: Gemini-SSI for surgical site infection prevention, Gemini-AKI for acute kidney injury prevention, and Gemini-CKD for chronic kidney disease treatment.